#phase3trial — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #phase3trial, aggregated by home.social.
-
Samsung Biologics Jumps 5% Premarket as Moderna Soars 177%
Samsung Biologics Samsung Biologics (207940.KS) surged nearly 6% in premarket trading after U.S. biotech firm Moderna reported significant…
#EuropeSays #Korea #KR #SamsungBiologics #CDMO #Koreanbiotechstocks #Merck #Moderna #mRNAcancervaccine #Phase3trial #Samsung
https://www.europesays.com/korea/125592/ -
AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu
MT Newswires -Shutterstock AstraZeneca (AZN.L, AZN.ST) on Monday announced mixed late-stage lung cancer trial results, shuttering its volrustomig…
#EuropeSays #Britain #Europe #EU #AstraZeneca #cervicalcancer #combinationtreatment #Lungcancer #non-smallcelllungcancer #Phase3trial
https://www.europesays.com/britain/105007/ -
https://www.europesays.com/britain/105007/ AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu #AstraZeneca #CervicalCancer #CombinationTreatment #LungCancer #NonSmallCellLungCancer #Phase3Trial
-
https://www.europesays.com/dk/?p=144897 Novo Nordisk’s ziltivekimab misses Phase 3 primary endpoint #ARTEMISTrial #ASCVD #CardiometabolicDisease #CardiovascularInflammation #CKD #CorvidiaTherapeutics #HERMESTrial #IL6Inhibitor #MACE #MonoclonalAntibody #NonCashImpairmentCharge #NovoNordisk #Phase3Trial #ZEUSTrial #ziltivekimab
-
DATE: August 12, 2026 at 08:01AM
SOURCE: STAT NEWS MENTAL HEALTHTITLE: STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial
URL: https://www.statnews.com/2026/08/12/definium-lsd-treatment-anxiety-study/?utm_campaign=rss
Definium Therapeutics said Wednesday that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of two large trials.
It’s the second major win for Definium in the past two months, following a Phase 3 success in major depression.
In the Phase 3 anxiety study, 214 patients were randomly assigned to receive a single dose of DT120 — Definium “proprietary, pharmaceutically optimized” LSD pill — or a placebo.
Continue to STAT+ to read the full story…
URL: https://www.statnews.com/2026/08/12/definium-lsd-treatment-anxiety-study/?utm_campaign=rss
-------------------------------------------------
STAT News reports "from the frontiers of health and medicine".
Learn more at https://www.statnews.com/topic/mental-health/ .
See also their complete Mastodon account at @STAT .
This robot is NOT affiliated with STAT news and merely rebroadcasts from their site. Responses posted here are not monitored.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #LSDtherapy #AnxietyTreatment #DefiniumTherapeutics #DT120 #GeneralizedAnxietyDisorder #Phase3Trial #PsychedelicMedicine #MentalHealthInnovation #PharmaNews #StatNews
-
DATE: August 12, 2026 at 08:01AM
SOURCE: STAT NEWS MENTAL HEALTHTITLE: STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial
URL: https://www.statnews.com/2026/08/12/definium-lsd-treatment-anxiety-study/?utm_campaign=rss
Definium Therapeutics said Wednesday that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of two large trials.
It’s the second major win for Definium in the past two months, following a Phase 3 success in major depression.
In the Phase 3 anxiety study, 214 patients were randomly assigned to receive a single dose of DT120 — Definium “proprietary, pharmaceutically optimized” LSD pill — or a placebo.
Continue to STAT+ to read the full story…
URL: https://www.statnews.com/2026/08/12/definium-lsd-treatment-anxiety-study/?utm_campaign=rss
-------------------------------------------------
STAT News reports "from the frontiers of health and medicine".
Learn more at https://www.statnews.com/topic/mental-health/ .
See also their complete Mastodon account at @STAT .
This robot is NOT affiliated with STAT news and merely rebroadcasts from their site. Responses posted here are not monitored.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #LSDtherapy #AnxietyTreatment #DefiniumTherapeutics #DT120 #GeneralizedAnxietyDisorder #Phase3Trial #PsychedelicMedicine #MentalHealthInnovation #PharmaNews #StatNews
-
DATE: August 12, 2026 at 08:01AM
SOURCE: STAT NEWS MENTAL HEALTHTITLE: STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial
URL: https://www.statnews.com/2026/08/12/definium-lsd-treatment-anxiety-study/?utm_campaign=rss
Definium Therapeutics said Wednesday that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of two large trials.
It’s the second major win for Definium in the past two months, following a Phase 3 success in major depression.
In the Phase 3 anxiety study, 214 patients were randomly assigned to receive a single dose of DT120 — Definium “proprietary, pharmaceutically optimized” LSD pill — or a placebo.
Continue to STAT+ to read the full story…
URL: https://www.statnews.com/2026/08/12/definium-lsd-treatment-anxiety-study/?utm_campaign=rss
-------------------------------------------------
STAT News reports "from the frontiers of health and medicine".
Learn more at https://www.statnews.com/topic/mental-health/ .
See also their complete Mastodon account at @STAT .
This robot is NOT affiliated with STAT news and merely rebroadcasts from their site. Responses posted here are not monitored.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #LSDtherapy #AnxietyTreatment #DefiniumTherapeutics #DT120 #GeneralizedAnxietyDisorder #Phase3Trial #PsychedelicMedicine #MentalHealthInnovation #PharmaNews #StatNews
-
GSK, Hansoh Lung Cancer Drug Hits Main Survival Goal in China Trial
British drugmaker GSK and its Chinese partner Hansoh Pharmaceutical have reported that their targeted cancer therapy, known as…
#EuropeSays #Britain #Europe #EU #GSK #antibodydrugconjugate #cancertreatmentinnovation #Chinaclinicaltrial #globaloncologypipeline #HansohPharmaceutical #Oncology #overallsurvival #Phase3trial #progression-freesurvival #ris-rez #smallcelllungcancer #targetedtherapy
https://www.europesays.com/britain/81834/ -
https://www.europesays.com/britain/81834/ GSK, Hansoh Lung Cancer Drug Hits Main Survival Goal in China Trial #AntibodyDrugConjugate #CancerTreatmentInnovation #ChinaClinicalTrial #GlobalOncologyPipeline #GSK #HansohPharmaceutical #Oncology #OverallSurvival #Phase3Trial #ProgressionFreeSurvival #RisRez #SmallCellLungCancer #TargetedTherapy
-
Sanofi posts positive Nexviazyme phase 3 IOPD data | SNY SEC Filing
About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling…
#France #FR #Europe #EU #Sanofi #Baby-COMET #biopharma #enzymereplacementtherapy #infantile-onsetPompe #labelextension #Nexviazyme #phase3trial #Pompedisease #SNY
https://www.europesays.com/france/47935/ -
https://www.europesays.com/dk/79802/ Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease #Etavopivat #Haemoglobin #HIBISCUS #JacobMartin #NovoNordisk #Phase3Trial #placebo #RedBloodCells #RegulatoryApproval #SickleCellDisease #StandardOfCare #ToplineResults #VasoOcclusiveCrisis
-
https://www.europesays.com/dk/65042/ Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease #Etavopivat #Haemoglobin #HIBISCUS #JacobMartin #NovoNordisk #Phase3Trial #placebo #RedBloodCells #RegulatoryApproval #SickleCellDisease #StandardOfCare #ToplineResults #VasoOcclusiveCrisis
-
https://www.europesays.com/dk/64499/ Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease #Etavopivat #Haemoglobin #HIBISCUS #JacobMartin #NovoNordisk #Phase3Trial #placebo #RedBloodCells #RegulatoryApproval #SickleCellDisease #StandardOfCare #ToplineResults #VasoOcclusiveCrisis